title: Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
authors.affiliation: Department of Medicine, University of Kentucky, Lexington.
authors.forename: T H
authors.initials: TH
authors.lastname: Waid
authors.forename: B A
authors.initials: BA
authors.lastname: Lucas
authors.forename: J S
authors.initials: JS
authors.lastname: Thompson
authors.forename: L C
authors.initials: LC
authors.lastname: Munch
authors.forename: S
authors.initials: S
authors.lastname: Brown
authors.forename: R
authors.initials: R
authors.lastname: Kryscio
authors.forename: R
authors.initials: R
authors.lastname: Prebeck
authors.forename: M A
authors.initials: MA
authors.lastname: VanHoy
authors.forename: D
authors.initials: D
authors.lastname: Jezek
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000150:complications; D004311:Double-Blind Method; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D007958:Leukocyte Count; D016853:Muromonab-CD3; D011446:Prospective Studies; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell